NovelMed Advances NM5072 for Multiple Ocular Disorders

Key Highlights Multi-indication precedent: Biogen’s approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan.Primate proof of concept: A single intravitreal dose of NM5072 reduced CNV, hemorrhage, and retinal fibrosis in a rhesus monkey model.Phase I clinical experience: NM5072 completed a Phase I study in 48 healthy volunteers and received FDA Orphan Drug Designation for PNH.Potential extended durability: Rabbit PK/PD data